Insights on Growth of Psoriatic Arthritis Market with Technical Advancement to 2023

****** Psoriatic Arthritis Market report explores future trends for supply, demand and market growth rate, market size, prices, trading, competition and value chain as well as Key Players of the industry’s information with forecast from 2019 to 2023.

****** Psoriatic ArthritisMarket Synopsis:

The ****** Psoriatic Arthritis Market research report is the study prepared by analysts, which contain a detailed analysis of drivers, restraints, and opportunities along with their impact on the Psoriatic Arthritis Market growth (2019 – 2023).

This report studies the ****** Psoriatic Arthritis Market over the forecast period of 2019 to 2023. The ****** Psoriatic Arthritis Market is expected to grow at an impressive Compound Annual Growth Rate (CAGR) from 2019 to 2023.

Get Sample Study Papers of “****** Psoriatic Arthritis Market” @ .

Psoriatic arthritis is a form of chronic inflammatory arthritis which affects the toes and fingers of the patient, gradually moving to skin and nails. While the clinical symptoms vary, the most commonly recognized symptoms of psoriatic arthritis are enthesitis, axial disease, peripheral arthritis, and dactylitis.

The rising number of elderly people across the globe has been one of the prime market catalysts. As aging increases the risk of psoriatic arthritis, the ****** demand for psoriatic arthritis pharmacotherapy is augmenting. The market will also benefit significantly from the introduction of blockbuster drugs including Vicodin and Simponi, apart from several other medications that are presently in the pipeline.

Geographically, North America has been ahead of the curve. The high amount of investment in healthcare has made it possible for the countries in these regions to offer advanced medical facilities. The growing geriatric population and the presence of leading pharmaceutical companies in this region have been some other prominent growth drivers of the ****** psoriatic arthritis market.

MajorPlayers profiled in the Psoriatic Arthritis Marketreport incorporate: F. Hoffmann-La Roche Ltd, Abbott Laboratories, Merck & Co, Inc., Pfizer, Inc., Novartis International AG, Johnson & Johnson, and Amgen, Inc.

Latest Industry News

1  Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.1 XELJANZ is the first and only oral Janus kinase (JAK) inhibitor to be approved in the European Union (EU) for the treatment of adults with active PsA. In 2017, XELJANZ in combination with MTX was approved in the EU for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs.

“People living with psoriatic arthritis may experience a variety of symptoms, making the condition particularly difficult to diagnose and treat,”said Angela Lukin, Regional President, Inflammation and Immunology, Pfizer. “Psoriatic arthritis, a chronic inflammatory condition which affects between 1.5 and 3 million people in Europe, causes joint pain and swelling that can eventually lead to permanent joint damage if not diagnosed and treated sufficiently early on,” said Frank Behrens, Rheumatology at Goethe University and Fraunhofer IME-Translational Medicine & Pharmacology, Frankfurt, Germany.

2  Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9% achieved PASI 90 by week 12, with 87% of patients reaching PASI 90 by week 16. In patients treated with Cosentyx 150mg, 87.8% achieved PASI 75 and 66.4% achieved PASI 90 at week 12.

Request a Discount on standard prices of this premium report @ .

Region segment: This report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Psoriatic Arthritis in these regions, from 2014 to 2023 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America.

Significant points in table of contents: Market Definition, Market Overview, Business Introduction, Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation (Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost Analysis, and Conclusion.

Report contents include

1  Analysis of the Psoriatic ArthritisMarket including revenues, future growth, market outlook

2  Historical data and forecast

3  Regional analysis including growth estimates

4  Analyzes the end user markets including growth estimates.

5  Profiles on Psoriatic Arthritisincluding products, sales/revenues, and market position

6  Market structure, market drivers and restraints.

About us is digital database of comprehensive market reports for ****** industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.